FDA's Monthly Video Series Wins Award

The U.S. Food and Drug Administration"FDA Patient Safety News," the FDA's monthly video series for health care professionals, has won the Cheers Award from the Institute for Safe Medication Practices (ISMP) for efforts to improve the safe use of medical products and prevent medical errors.

The ISMP Cheers Awards honors organizations that have set a superior standard of excellence for others to follow in the prevention of medication errors and adverse drug events.

"FDA Patient Safety News" is broadcast monthly over several medical satellite television networks to more than 4,500 U.S. hospitals and long-term care facilities. It conveys safety information about drugs, devices and vaccines directly from the FDA to physicians, pharmacists, nurses, risk managers and educators across the country; reports on recalls and safety alerts and medical errors; and provides tips on how to protect patients.

The program's video format makes possible the demonstration of patient protection techniques; showing of recalled and counterfeit products; illustrating how medical errors occur; and demonstrating how to reduce risks when using medical products.

In addition to the monthly satellite broadcasts, a link to the show is distributed by e-mail every month to approximately 170,000 subscribers. The program also has its own Web page, http://www.fda.gov/psn, where viewers can download the videos or watch them online, read or print the story scripts, or subscribe to receive the program via video podcasting or RSS feed—all free of charge.

"FDA Patient Safety News" is intended primarily for a professional audience. However, on the assumption that health care professionals will discuss these topics with their patients, some of the videos include information for patients or consumers.

Most Popular Now

Chemists characterize the fatal fungus among us

Life-threatening fungal infections affect more than two million people worldwide. Effective antifungal medications are very limited. Until now, one of the major challenge...

FDA approves first cancer drug through new oncolog…

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopa...

Discovery of kidney cancer driver could lead to ne…

University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic...

The immune system: T cells are built for speed

Without T cells, we could not survive. They are a key component of our immune system and have highly sensitive receptors on their surface that can detect pathogens. The e...

Pfizer initiates pivotal Phase 3 program for inves…

Pfizer Inc. (NYSE:PFE) and Spark Therapeutics (NASDAQ:ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study (NCT03587116) to evalu...

FDA approves first targeted treatment for patients…

The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (...

Sanofi and REVOLUTION Medicines launch global part…

Sanofi and REVOLUTION Medicines, Inc. today announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cell...

Novartis renews drug donation of Egaten® (triclabe…

Novartis reaffirms its commitment to the fight against liver fluke (fascioliasis), signing a renewed memorandum of understanding with the World Health Organization (WHO) ...

Women and older people under-represented in drug t…

Trying to determine how best to treat a patient, doctors often look to randomized clinical trials to guide their choice of what drug to prescribe. One of the most common ...

New findings suggest allergic responses may protec…

The components of the immune system that trigger allergic reactions may also help protect the skin against cancer, suggest new findings. The research, led by Imperial Col...

FDA grants Breakthrough Therapy Designation for Ro…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) i...

Novartis marks a new era for migraine patients wit…

Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days p...